Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy

What was studied

This study evaluated niraparib (a PARP inhibitor) as maintenance therapy in patients with primary advanced or recurrent endometrial cancer who received dostarlimab (a PD-1 inhibitor) plus chemotherapy as first-line or subsequent treatment.